Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Metastatic Melanoma

NCT04072900 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.

NCT NCT04072900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04072900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Metastatic Melanoma
Lead sponsor
Xiangya Hospital of Central South University
Phase
Phase 1
Overall status
Unknown status
Start date
April 21, 2020
Completion date
September 1, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)